Russell Investments Group, Ltd. C4 Therapeutics, Inc. Transaction History

Russell Investments Group, Ltd.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$1.81 - $3.89 $32,017 - $68,810	17,689 Added 22.64%	95,822 $178,000
Q2 2023 Aug 10, 2023	BUY	$2.75 - $3.77 $52,522 - $72,003	19,099 Added 32.35%	78,133 $214,000
Q1 2023 May 09, 2023	BUY	$3.1 - $9.02 $42,773 - $124,457	13,798 Added 30.5%	59,034 $185,000
Q4 2022 Feb 08, 2023	BUY	$5.42 - $10.24 $39,257 - $74,168	7,243 Added 19.06%	45,236 $266,000
Q3 2022 Nov 04, 2022	SELL	$8.03 - $12.77 $5,203 - $8,274	-648 Reduced 1.68%	37,993 $332,000
Q2 2022 Jul 29, 2022	BUY	$5.06 - $26.46 $195,523 - $1.02 Million	38,641 New	38,641 $290,000
Q4 2021 Jan 21, 2022	SELL	$29.39 - $46.86 $148,595 - $236,924	-5,056 Closed	0 $0
Q3 2021 Nov 08, 2021	BUY	$35.91 - $50.5 $161,379 - $226,947	4,494 Added 799.64%	5,056 $225,000
Q2 2021 Aug 04, 2021	BUY	$30.39 - $42.18 $17,079 - $23,705	562 New	562 $21,000

130

63.5M

670K

54.8K

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $178M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

Stay updated on Russell Investments Group, Ltd. with notifications on news.